Effect of metabolic dysfunction‐associated steatotic liver disease on BNT162b2 immunogenicity against the severe acute respiratory syndrome coronavirus 2 omicron variant

Author:

Lam Lok Ka1,Tan Jing Tong1,Ooi Poh Hwa1,Zhang Ruiqi1,Chan Kwok Hung2,Mao Xianhua1,Hung Ivan F N1,Seto Wai Kay134ORCID,Yuen Man Fung14,Cheung Ka Shing13ORCID

Affiliation:

1. Department of Medicine, School of Clinical Medicine The University of Hong Kong, Queen Mary Hospital Pok Fu Lam Hong Kong

2. Department of Microbiology The University of Hong Kong, Queen Mary Hospital Pok Fu Lam Hong Kong

3. Department of Medicine The University of Hong Kong‐Shenzhen Hospital Shenzhen China

4. State Key Laboratory of Liver Research The University of Hong Kong Pok Fu Lam Hong Kong

Abstract

AbstractBackground and AimWe aimed to investigate the effect of metabolic dysfunction‐associated steatotic liver disease (MASLD) on three‐dose BNT162b2 immunogenicity to the omicron variant.MethodsAdult recipients of three doses of BNT162b2 were prospectively recruited between May and December 2021. The serology of the neutralizing antibody by live virus microneutralization (vMN) to the omicron variant was measured at baseline, day 180, and day 360 after the first dose. The primary outcome was seroconversion (vMN titer ≥ 10) at day 360. Exposure of interest was MASLD, defined as hepatic steatosis (controlled attenuation parameter ≥ 248 dB/m on transient elastography) plus at least one of five cardiometabolic risk factors. Subjects with prior COVID‐19 were excluded. A multivariable logistic regression model was used to derive the adjusted odds ratio of seroconversion with MASLD by adjusting for age, sex, antibiotic use, and proton pump inhibitor use.ResultsOne hundred forty‐eight BNT162b2 recipients (male: 48 [32.4%]; median age: 51.0 years [interquartile range, IQR: 44.5–57.3]) were recruited. The median time from the first dose to the third dose was 8.5 months (IQR: 7.9–8.9). MASLD subjects had a lower seroconversion rate than non‐MASLD ones (89.6% vs 99.0%; P = 0.007). MASLD was the only independent risk factor for seroconversion (adjusted odds ratio: 0.051, 95% confidence interval: 0.002–0.440). Subgroup analysis of immunogenicity at 4 months after the third dose shows significantly lower vMN titer (13.06 [IQR: 7.69–22.20] vs 33.49 [IQR: 24.05–46.53]; P = 0.004) and seroconversion rate (76.9% vs 97.4%; P = 0.016) in MASLD than non‐MASLD subjects, but not within 4 months from the third dose (vMN titer: 46.87 [IQR: 33.12–66.02] vs 41.86 [IQR: 34.47–50.91], P = 0.240; seroconversion rate: 94.3% vs 100%, P = 0.131).ConclusionMetabolic dysfunction‐associated steatotic liver disease was a risk factor for poorer immunogenicity to the omicron variant, with a more pronounced waning effect compared among three‐dose BNT162b2 recipients.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3